Ertugliflozin PBS listing offers more triple therapy options in T2D

The SGLT2 inhibitor drug ertugliflozin is now listed on PBS for use as triple oral therapy in patients with Type 2 diabetes mellitus in fixed dose combination (FDC) products with sitagliptin or metformin. Marketed under the brand name Steglatro by MSD, the drug was PBS listed on 1 December 2018 for patients with uncontrolled T2DM (as ...

Already a member?

Login to keep reading.

© 2021 the limbic